

Supplemental Table 1. Positive rate of T/M ratio and other biomarkers in pulmonary metastatic tumors

	High T/M ratio	Glut1	Glut3	Hexo I	HIF-1 α	VEGF	CD34
All cases (n=146)	79 (55%)	104 (73%)	10 (7%)	82 (57%)	102 (71%)	70 (49%)	63 (44%)
Colon cancer (n=80)	48 (60%)	66 (83%)	1 (1.3%)	41 (51%)	60 (75%)	36 (45%)	22 (28%)
Sarcoma (n=17)	5 (29%)	4 (24%)	2 (12%)	5 (29%)	5 (29%)	5 (29%)	9 (53%)
Head and neck cancer (n=14)	5 (33%)	9 (64%)	2 (14%)	9 (64%)	8 (67%)	6 (43%)	8 (67%)
Breast cancer (n=9)	4 (44%)	7 (78%)	1 (11%)	9 (100%)	9 (100%)	7 (78%)	7 (78%)
Genital cancer (n=12)	8 (66%)	11 (92%)	2 (17%)	10 (83%)	10 (83%)	8 (67%)	7 (58%)
Gastrointestinal cancer (n=10)	7 (70%)	6 (60%)	0 (0%)	5 (50%)	8 (80%)	6 (60%)	8 (80%)
Other (n=4)	2 (50%)	1 (25%)	2 (50%)	3 (75%)	2 (50%)	2 (50%)	2 (50%)

Abbreviation: Glut1, glucose transporter 1; Glut3, glucose transporter 3; Hexo I, hexokinase I; VEGF, vascular endothelial growth factor.

Supplemental Table 2. Relationship between FDG uptake and expression of biomarkers

Biomarker	Glut1	Glut3	Hexo I	HIF-1 α	VEGF	CD34
Metastases (n=146)						
Spearman γ	0.4579	-0.0552	0.3921	0.3654	0.5528	0.2342
95% CI	0.3147 to 0.5806	-0.2204 to 0.1130	0.2407 to 0.5249	0.2111 to 0.5019	0.4248 to 0.6591	0.0696 to 0.3862
<i>p</i> -value	< 0.0001	0.5078	< 0.0001	< 0.0001	< 0.0001	0.0044
AC (n=103)						
Spearman γ	0.4043	0.0226	0.2851	0.2628	0.4814	0.2036
95% CI	0.2232 to 0.5585	-0.1773 to 0.2208	0.0911 to 0.4582	0.0672 to 0.4390	0.3122 to 0.6210	0.0046 to 0.3870
<i>p</i> -value	<0.0001	0.8202	0.0035	0.0073	<0.0001	0.0391
SQC (n=13)						
Spearman γ	0.5805	-0.5189	0.5716	0.6858	0.6841	0.0359
95% CI	0.0249 to 0.8621	-0.8376 to 0.063	0.0116 to 0.8586	0.1990 to 0.9011	0.1960 to 0.9006	-0.5387 to 0.5878
<i>p</i> -value	0.0375	0.0692	0.0413	0.0097	0.0099	0.9071
Sarcoma (n=17)						
Spearman γ	0.6654	0.2196	0.6932	0.7118	0.7106	0.2603
95% CI	0.2572 to 0.8721	-0.3060 to 0.6427	0.3046 to 0.8839	0.3376 to 0.8917	0.3355 to 0.8912	-0.2664 to 0.6673
<i>p</i> -value	0.0036	0.3970	0.0020	0.0014	0.0014	0.3130
Lung cancer (n=138)						
Spearman γ	0.7355	0.0736	0.7046	0.7088	0.7033	0.6691
95% CI	0.6451 to 0.8056	-0.0995 to 0.2426	0.6061 to 0.7818	0.6113 to 0.7851	0.6045 to 0.7809	0.5617 to 0.7543
<i>p</i> -value	< 0.0001	0.3905	< 0.0001	< 0.0001	< 0.0001	<0.0001
AC (n=93)						
Spearman γ	0.7365	0.0492	0.7063	0.6327	0.6990	0.6529
95% CI	0.6231 to 0.8196	-0.1620 to 0.2563	0.5830 to 0.7978	0.4877 to 0.7437	0.5735 to 0.7925	0.5136 to 0.7487
<i>p</i> -value	< 0.0001	0.6389	< 0.0001	< 0.0001	< 0.0001	< 0.0001
SQC (n=45)						
Spearman γ	0.3448	0.0218	0.4524	0.6492	0.3808	0.2892
95% CI	0.0480 to 0.5856	-0.2818 to 0.3215	0.1745 to 0.6636	0.4320 to 0.7952	0.0892 to 0.6122	-0.0137 to 0.5435
<i>p</i> -value	0.0204	0.8869	0.0018	< 0.0001	0.0099	0.0540
Control group (n=29)						
Spearman γ	0.4930	0.3376	0.5162	0.2828	0.2353	0.0351
95% CI	0.1432 to 0.7333	-0.0444 to 0.6335	0.1735 to 0.7474	-0.1047 to 0.5958	-0.1543 to 0.5619	-0.1260 to 0.5817
<i>p</i> -value	0.0066	0.0733	0.0041	0.1372	0.2191	0.1684